There are actually three separate eligibility questions, and conflating them is the source of most confusion. Whether the medication is FDA-approved for someone like you. Whether a clinician judges it appropriate for you specifically. And whether your insurer will pay for it.
You can clear the first two and fail the third — that is, in fact, the most common outcome. This guide covers all three.
The FDA-Approved Criteria
GLP-1 medications approved for chronic weight management share a broadly similar indication structure: adults with obesity, or adults with overweight plus at least one weight-related condition, used alongside a reduced-calorie diet and increased physical activity.
| Category | Typical Threshold | Additional Requirement |
|---|---|---|
| Obesity | BMI 30 or higher | None beyond the BMI threshold |
| Overweight | BMI 27 or higher | At least one weight-related condition |
| Weight-related conditions | Hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease | Documented by your clinician |
Indications Differ by Product
Individual medications carry their own approved indications, which have expanded over time. Zepbound, for example, also carries an approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity. Semaglutide products carry additional approved indications including cardiovascular risk reduction in certain patients.
Always check the specific prescribing information for the medication you are considering rather than assuming a single set of criteria applies across the class.
What Disqualifies You
Absolute Contraindications
These are not negotiable and no legitimate provider will work around them:
- Personal or family history of medullary thyroid carcinoma (MTC) — GLP-1 receptor agonists as a class carry an FDA boxed warning for thyroid C-cell tumors
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — same boxed warning basis
- Known serious hypersensitivity to the medication or any of its components
- Pregnancy — GLP-1s are not for use in pregnancy
Conditions Requiring Careful Evaluation
These do not automatically rule you out, but they require genuine clinical judgement and are reasons to prefer a provider with real clinical depth over a fast-prescribing platform:
- History of pancreatitis
- Gallbladder disease
- Severe gastrointestinal disease, including gastroparesis
- Diabetic retinopathy in patients with type 2 diabetes
- History of eating disorders, particularly restrictive patterns
- Severe kidney impairment
- Concurrent use of insulin or sulfonylureas, which raises hypoglycemia risk
- Planning pregnancy in the near term
A Note on Eating Disorder History
This deserves more attention than most intake questionnaires give it. GLP-1s suppress appetite substantially, which can reinforce restrictive patterns in people with a history of anorexia or other restrictive eating disorders. If this is part of your history, disclose it — and seek a provider with genuine clinical depth rather than one that will not ask.
The Insurance Hurdle Is Separate
Meeting the FDA criteria and having a clinician agree does not mean your insurance will pay. These are entirely different determinations, made by different parties, using different standards.
knownwell’s own published analysis notes that nearly two-thirds of Americans with insurance are in plans that either exclude all, or cover only one, new-generation obesity medication. Coverage for diabetes indications is considerably more common than coverage for weight management.
What Prior Authorization Typically Requires
- Documented BMI meeting your plan’s threshold, which may be stricter than the FDA indication
- Documented weight-related comorbidities
- Evidence of prior weight-loss attempts, sometimes including a documented supervised diet trial
- Step therapy — trying and failing a cheaper medication first, in some plans
- Ongoing documentation of progress to maintain approval
If You Are Denied, Appeal
Denials are common and appeals succeed often enough to be worth the effort. A letter from your clinician documenting comorbidities, prior treatment failures and medical necessity is the single most effective tool.
Specialists carry more weight here. A board-certified obesity medicine physician documenting necessity — as at Form Health — is more persuasive to a utilization reviewer than a general telehealth prescriber.
But if your plan excludes the drug class outright, no appeal will change that. At that point, stop pursuing coverage and price the cash-pay market instead.
How Providers Actually Assess You
Assessment depth varies enormously across this market, and it is worth knowing what you are getting.
| Provider Type | Typical Assessment | Examples |
|---|---|---|
| Obesity medicine clinics | Thorough intake, labs, comorbidity evaluation, specialist review | Form Health, knownwell |
| Primary care platforms | Full medical history within an ongoing care relationship | Amazon One Medical, PlushCare |
| Specialized practices | Population-specific evaluation (e.g. menopause, hormone health) | Alloy, Midi Health, Zeus Health |
| Cash-pay telehealth | Online questionnaire reviewed by a licensed clinician | Most compounded providers |
| Manufacturer pharmacies | No assessment — you bring an existing prescription | LillyDirect, NovoCare Pharmacy |
A Warning Sign Worth Taking Seriously
A study reported that a simulated patient in the United States received GLP-1 prescriptions from 45 of the 49 websites they approached. The FDA has also issued warnings to telehealth companies over promotional claims about unapproved GLP-1 products.
A provider that will prescribe to almost anyone is not doing you a favour. Screening exists to catch the contraindications above, and a platform that does not screen properly is a platform that will not catch yours.
If You Do Not Qualify
Being ineligible for a GLP-1 is not the end of medical weight management. Several routes remain:
- Non-GLP-1 medications. Several FDA-approved anti-obesity medications work through different mechanisms. Found offers non-GLP-1 plan options starting at $49/month, and obesity medicine specialists prescribe across the full range.
- Obesity medicine consultation. A board-certified specialist can evaluate whether a different pharmacotherapy suits you, or whether an underlying condition is driving the weight change.
- Metabolic and bariatric surgery. For patients meeting surgical criteria, this remains the most effective long-term intervention available.
- Address the barrier directly. If you were declined for a modifiable reason — an untreated condition, a medication interaction — resolving it may make you eligible later.
The Bottom Line
Clinical eligibility generally means BMI 30 or higher, or BMI 27 or higher with a weight-related condition — but the specific approved indication varies by medication, so check the one you are considering.
Contraindications are absolute. A personal or family history of medullary thyroid carcinoma or MEN 2 rules out GLP-1 therapy entirely, and pregnancy is a hard exclusion. Disclose everything at intake, including any history of eating disorders.
Insurance eligibility is a separate fight, and most insured Americans are in plans that exclude or severely limit obesity medication. Appeal denials with specialist documentation — but if your plan excludes the class outright, move to the cash-pay market instead.
A provider that prescribes to everyone is a red flag, not a convenience. If you have any complexity in your history, choose a provider with real clinical depth. See our insurance-accepting provider ranking or Coreage RX for straightforward cash-pay access.
Frequently Asked Questions
What BMI do I need for a GLP-1?
Generally 30 or higher for obesity, or 27 or higher with at least one weight-related condition such as hypertension, type 2 diabetes, dyslipidemia or obstructive sleep apnea. Specific approved indications vary by medication, and insurers frequently apply stricter thresholds than the FDA indication does.
Can I get a GLP-1 without any comorbidities?
If your BMI is 30 or above, yes — obesity alone generally meets the indication. Below 30, you typically need a documented weight-related condition. Your clinician makes this determination.
Does a family history of thyroid cancer disqualify me?
A personal or family history of medullary thyroid carcinoma specifically, or MEN 2, is a contraindication for GLP-1 receptor agonists based on the class boxed warning. Other thyroid conditions are a different question — discuss your specific history with your clinician rather than assuming either way.
Will my insurance cover it if I meet the criteria?
Not necessarily, and often not. Meeting the FDA indication and meeting your plan’s coverage criteria are separate. knownwell’s published analysis notes that nearly two-thirds of insured Americans are in plans that exclude all, or cover only one, new-generation obesity medication.
What if I have a history of an eating disorder?
Disclose it. GLP-1s substantially suppress appetite, which can reinforce restrictive patterns. This does not automatically disqualify you, but it requires genuine clinical judgement — and it is a strong reason to choose a provider with real clinical depth rather than a fast-prescribing platform.
Can I get a GLP-1 while pregnant or trying to conceive?
GLP-1s are not for use in pregnancy. If you are pregnant, planning pregnancy, or of childbearing potential, discuss contraception and pregnancy planning explicitly with your prescriber before starting. Delayed gastric emptying can also affect absorption of oral medications including some contraceptives.
What if a provider approves me but I have a condition on the caution list?
Get a second opinion from a clinician with obesity medicine training. Conditions like pancreatitis history, gallbladder disease or gastroparesis require genuine evaluation, and a platform that waves them through is not exercising the judgement you are paying for.
What are my options if I am not eligible?
Non-GLP-1 anti-obesity medications work through different mechanisms and may be appropriate — Found offers non-GLP-1 plans from $49/month. An obesity medicine specialist can evaluate the full range. For patients meeting surgical criteria, metabolic and bariatric surgery remains the most effective long-term intervention.
⚕️ Medical Disclaimer:
This article is for informational purposes only and is not medical advice, diagnosis, or treatment. GLP-1 receptor agonists are prescription medications with serious risks and contraindications, including a boxed warning for thyroid C-cell tumors. Only a licensed clinician who knows your medical history can determine whether any weight-management medication is appropriate for you. See our full medical disclaimer.
Disclosure:
This article is based on publicly available information including FDA public communications, manufacturer prescribing information summaries, published clinical literature, and provider-published materials, current as of August 2026. Presidential GLP-1 may receive compensation from some providers featured on this site, which helps us provide free, independent reviews. Eligibility criteria described here are general and approved indications vary by medication and have expanded over time — always check the specific prescribing information for the medication you are considering. Insurance criteria are set by individual plans and are frequently stricter than FDA indications. Nothing here is medical advice; eligibility determinations must be made by a licensed clinician who knows your full history.
Related Reading
GLP-1s, Fertility and Birth Control
Restored fertility, the contested contraception evidence, and what to ask before starting.
GLP-1s Beyond Weight Loss
Zepbound for sleep apnea, Wegovy for cardiovascular risk, and what that means for coverage.
Insurance, HSA and FSA Guide
How prior authorization works and what to do when coverage is denied.
How to Vet a GLP-1 Provider
The questions that separate legitimate providers from the rest.
Best Providers That Take Insurance
Where coverage actually works, including Medicare pathways.
How GLP-1 Medications Work
The mechanism behind appetite suppression and weight loss.